Synthelis raises funding
Synthelis, a company specializing in the production and characterization of therapeutic targets and antigens, has secured initial backing from a group of French investors. Backers include Rhone-Alpes Creation, Alpes Developpement Durable Investissement, Sud Rhone-Alpes Capital, Viaduc and the Savoy and Grenoble Business Angels networks.
21 January 2014•6 mins read
